Indeed, GSK2606414 was shown to exert neuroprotective effects in tauopathies and Parkinson's and Alzheimer's diseases as a selective inhibitor of PERK (Halliday et al., 2015; Radford et al., 2015). Here, EIF2AK3 is linked to early-onset autosomal dominant Alzheimer disease.